Invokana / Farxiga / Jardiance / Invokamet / Xigduo / Glyxambi / Synjardy / Qtern / Steglatro / Steglujan / Segluromet
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The diabetes drugs Invokana, Farxiga, and Jardiance — as well as Invokamet, Xigduo, Glyxambi, Synjardy, Qtern, Steglatro, Steglujan, and Segluromet — have been associated with the serious side effects Fournier’s Gangrene and Necrotizing Fasciitis of the Perineum.
All of these diabetes drugs are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, an increasingly popular class of Type-2 diabetes medicines.
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have been diagnosed with Fournier’s Gangrene or Necrotizing Fasciitis of the Perineum.
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About These Drugs
Since being approved by the FDA as diabetes drugs years ago, Invokana, Farxiga, and Jardiance — as well as Invokamet, Xigduo, Glyxambi, Synjardy, Qtern, Steglatro, Steglujan, Segluromet, and other SGLT2 inhibitors — have been associated with other side effects, or adverse drug reactions, such as Fournier’s gangrene and necrotizing fasciitis of the perineum. Now retinal vein occlusion has been linked to Invokana, Farxiga, Jardiance, and those several other SGLT2 inhibitors as a new vision/eyes side effect, according to a recent medical journal article.
To read more of this article, click below:
In June 2021 it was reported that Invokana, Farxiga, Jardiance, and other drugs in the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors class, are associated with an increased risk of retinal vein occlusion. This new SGLT2 inhibitors side effect was the subject of a presentation at the 81st Scientific Sessions of the American Diabetes Association which was based on the first study to examine the potential association of retinal vein occlusion with the use of SGLT2 inhibitors.
From this news report published on the PracticeUpdate website (free registration required), “ADA 2021: SGLT2 Inhibitors May Increase the Risk of Retinal Vein Occlusion”, we get these details:
In a subgroup analysis, significant interactions were evident with use SGLT2 inhibitors and risk of retinal vein occlusion concerning age ≥ 60 years (hazard ratio 1.53, 95% confidence interval 1.20–1.94, P =.0135) and estimated glomerular filtration rate < 60 mL/min/1.73 m2 (hazard ratio 3.13, 95% confidence interval 155–6.32, P = .0083). No significant interactions were evident for sex, age, body mass index, presence of comorbidities, multiple lifestyle factors, or use of other anti-diabetes agents.[The researchers concluded] “In a matched cohort study, we found that SGLT2 inhibitors were associated with a significantly increased risk of retinal vein occlusion. The elderly and patients with chronic kidney disease were at higher risk for retinal vein occlusion,”….
Of course, we will continue to monitor the medical literature for more about this new SGLT2 inhibitors side effect related to vision/eyes, retinal vein occlusion.[Read article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Questions Raised About Whether Fournier’s Gangrene Is A Side Effect Of Farxiga, Invokana, And Jardiance
- Cases Of Fournier Gangrene Associated With Diabetes Drugs Invokana, Jardiance, And Farxiga
- Lower Limb Amputations From All SGLT2 Inhibitors, or Just Invokana?
- Farxiga And Jardiance Have Two-Time Increased Risk For Amputations
- Amputations Are Diabetes Drugs Side Effects For SGLT2 Inhibitors Class
- Lower Limbs Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects
- Fournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance
- Increased Risks Of Lower-Limb Amputations For Farxiga And Jardiance
- Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations
- Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
- New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance
- Invokana – Amputations: No Explanation Yet As Regards “How” And “Why”
- “Dear Doctor” Letter About Invokana And Amputations Was Sent In Canada
- FDA Reports Show Extent And Nature of Invokana-Amputation Side Effect
- Jardiance, Invokana, And Farxiga Double Risk Of Diabetic Ketoacidosis
- Farxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits
- Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti
- New Federal Court Multidistrict Litigation (MDL) For Farxiga Lawsuits
- Invokana Has New Warning About Risk Of Lower Limb Amputation In Canada
All content by attorney Tom Lamb